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ABSTRACT
Lymphatic filariasis (LF) is a tropical disease caused by infection with the parasitic filarial worms: Wuchereria bancrofti, Brugia malayi, and Brugia 
timori. The symptoms of this chronic disease appear in adults (in men more than in women) and include damage to the lymphatic system, arms, 
legs, and genitals, which cause significant pain, reducing productivity, and social problems. LF is a cause of continued disability, pain, disfigurement, 
and sexual disability in the world, so the knowledge of the disease and the infection control is very important. In addition to the importance of 
prevention, that includes giving medicine and using controlling ways of mosquitoes. Moreover, the prevention of disease is important, that includes 
giving medicine and using controlling ways of mosquitoes. However, although the efforts of health organizations to reduce the LF infections, there are 
still many challenges including the early diagnosis and control of infection among people.
Keywords: Lymphatic filariasis, Lymphedema, Hydrocele, Mosquitoes.
INTRODUCTION
Lymphatic filariasis (LF) is the second most common mosquito-
borne disease globally. LF infection occurs by exposure to mosquito 
bites. There are three parasites, which cause human LF, Wuchereria 
bancrofti, Brugia malayi, and Brugia timori all of them are transmitted 
by Anopheles, Aedes, and Culex. W. bancrofti is responsible for more than 
90% of infections globally, while B. malayi is mostly contributed to the 
transmission of the remainder. The third parasite, B. timori, is common 
in a few countries in Southeast Asia [1].
These parasites block the body’s lymphatic nodes and vessels. This 
blockage causes fluids to collect in the tissues, which can lead to huge 
swelling, called “lymphedema” [2,3].
LF infection is chronic; this is due to the long life of the worms and 
accumulation of infection with time. Many people may be infected 
without being noticed, but after a long term, some people may develop 
severe chronic symptoms including hydrocele and lymphoedema [4].
HISTORY OF FILARIASIS
Although there are no manuscripts about LF before the 16th century, but 
the historical evidence of LF can be ratified through ancient artifacts 
which suggested that the disease may have been found about 2000 
BC such as a statue of Pharaoh Mentuhotep depicting swollen limbs 
(Fig. 1a) [5], also the replicas of illustrations which were found on the 
wall tomb of Tutankhamen depicting the prince of Punt and his wife 
who suffer from elephantiasis (Fig. 1b) [6].
Some early scientific discoveries in filariasis history include the 
following
Jean-Nicolas Demarquay found microfilariae in hydrocele liquid of 
a Cuban in Paris (1863). In 1866, Wucherer found microfilariae in 
chyluria, and it was found for the 1st time in blood samples by Lewis 
(1872). Bancroft recognized a female adult filarial worm in the 
lymph node ulcer of the arm (1877). In 1877, Sir Patrick Manson, 
the distinguished pioneer of tropical medicine found microfilariae 
in the stomach of bloodsucker mosquito and later, he detected the 
microfilariae nocturnal periodicity (1879). The name Filaria bancrofti 
was given by Cobbold, in 1877, and the generic name Wuchereria was 
given in 1878. Male adult worms were found by Sibthorpe (1888) while 
the male filaria was found in the seminiferous hydrocele by Shichiro 
Hida (1903). Erwin Von Baelz detected microfilariae in the blood 
(1876). In Tokyo, Yushitaro Matsuura found a female adult worm in an 
inguinal lymph node (1896). Later, a lot of work was done in defining 
various manifestations of filariasis and the aim of current researches is 
concentrated on prevalence, treatment, transmission cycles, and newly 
discovered species [6-10].
EPIDEMIOLOGY OF LF
There are 120 million people in tropical and subtropical areas of the 
world infected with LF, about 25 million men have the genital disease 
(hydrocele) and almost 15 million, mostly women, have lymphoedema 
or elephantiasis of the leg. The total population requiring preventative 
chemotherapy is 57% living in the Southeast Region of Asia (9 countries) 
and 37% living in the African Region (35 countries) [11].
Many kinds of mosquitoes can transmit the parasite, depending on the 
geographic area. For example, in Africa, the most common mosquito 
is Anopheles and in the Americas, it is Culex, Aedes and Mansonia can 
transmit the infection in the Pacific and Asia.
Many mosquito bites are needed to get LF. People who live for a long 
time in tropical and subtropical areas are at high risk for infection while 
the tourists have a very low risk [12,13].
ETIOLOGY
As we stated earlier, LF is caused by three filarial nematodes of the 
Filarioidea family, W. bancrofti (Fig. 2a), B. malayi (Fig. 2b), and B. timori 
(Fig. 2c) which have generally similar life cycles and transmitted from 
person to person by mosquitoes: Aedes (Fig. 3a), Anopheles (Fig. 3b), 
and Culex (Fig. 3c) [7,9,14-17].
FILARIASIS LIFE CYCLE
The extrinsic life cycle starts when the microfilariae are ingested with 
the human blood by a bite of a mosquito. The microfilariae migrate 
through the gut wall of the mosquito to thoracic muscles where they 
become shorter and thicker, later develop into the first-stage larvae 
(L1). After 5–7 days, the L1 grow and develop to become the second 
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stage (L2), which is more active and finally by 10–11 days, they develop 
to become the infective stage larvae (L3).
After maturity, most of the infective larvae (L3) move to the mosquito’s 
proboscis, where they become ready to infect another human (Fig. 4).
When the mosquito bites the host, L3 is put on the skin surface and after 
pulling the proboscis; they get into the wound and travel to the lymphatics. 
After about 9–10 days of entering, the L3  molt to become the fourth 
stage larvae (L4). The L4 stage needs several days to few months before it 
develops and becomes an adult. The adult male of W. bancrofti has a length 
of 23.8–30.6 mm and width of 90–120 μm. The length of the female is 
42.2–46.3 mm and width of 160–188 μm. In the human body, adult worms 
(male and female) live in lymph vessels and lymph nodes. After mating, the 
females produce numerous microfilariae, which migrate into the lymphatic 
system and spread through the bloodstream (Fig. 5) [7,8,14,18,23-25].
Symptoms
Most infected people have no symptoms and they do not know that 
they have LF unless tested [24]. At least half of all patients with LF 
are asymptomatic people. These asymptomatic infections gradually 
cause damage to the lymphatic system, kidneys, and disturbance in the 
body’s immune system and this is directly linked to the efficiency of 
the patient’s immune and may have acute inflammation of lymphatic 
vessels with high temperatures, chills, body aches, and swollen lymph 
nodes. Excessive amounts of fluid may accumulate in the affected 
tissues [24,27]. In chronic conditions, LF leads to lymphoedema (tissue 
swelling) (Fig. 6) or elephantiasis (skin thickening) (Fig. 7), and limbs 
and hydrocele swelling (scrotal swelling or breast swelling) (Fig. 8) and 
may develop to filarial abscesses [5,8,25,28-30].
Tropical pulmonary eosinophilia is another symptom of the LF infection, 
this is due to the high immune response to the filarial antigens, and its 
symptoms are excessive coughing causing in some cases chest pain due 
to fractures in ribs, breathlessness, and wheezing [24,31].
Diagnosis
The diagnosis of filariasis can be done by different methods such as follows:
• Blood tests: Blood counts are done, especially the eosinophils, in 
Fig. 4: The life cycle of the filarial parasite [26]
Fig. 3: The mosquitoes that transmit the disease: (a) Aedes [21], 
(b) Anopheles [22], (c) Culex [21]
c
ba
Fig. 2: (a) Wuchereria bancrofti [18], (b) Brugia timori [19], 
(c) Brugia malayi [20]
cba
Fig. 1: (a) Statue of Pharaoh Mentuhotep depicting swollen limb 
[5], (b) the princess of Punt with elephantiasis [6]
ba
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addition to the identification of microfilariae in a blood sample by 
taking the blood at night and staining it with Giemsa or hematoxylin 
and eosin. Identification of the type of microfilariae is done according 
Fig. 6: Lymphedema [32]
Fig. 7: Elephantiasis (skin thickening) [33]
Fig. 8: Scrotal swelling and breasts swelling [34]
Fig. 9: Differentiation of species of filariasis larva (L3) in human [18]
to the characteristics of the stage larva (L3) in human, such as 
the number and position of caudal nuclei, cephalic space, and the 
presence or absence of sheath (Fig. 9) [5,7-9,15,24,35,36].
Fig. 5: (a) Microfilaria in human blood, (b) microfilaria in mosquito, (c) first-stage larva (L1) in mosquito, (d) second-stage larva (L2) 
in mosquito, (e) third infective stage larva (L3) in mosquito, (f) third infective stage larva (L3) in human, (g) fourth-stage larva (L4) in 
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• Identification of microfilariae in a urine and hydrocele fluid: This is 
done by centrifuging the fluids samples, the resulting deposits are 
put on a slide, and examined under the microscope [7,9,30].
• Identification of adult worms in lymphatics: The motile adult worms 
can be seen within the lymphatics of scrotum, breast, thigh, and the 
spermatic cord in infected tissue using ultrasonography [5,7,9,15,36].
• Immunological tests: Such as antigen assays (TropBio Og4C3 Test 
[TropBio, Australia], immunochromatographic card test), antibody 
assays, and polymerase chain reaction [5,7,8,9,15,24,30,37,38].
Treatment and prevention
The World Health Organization (WHO) has identified the dangerous 
of LF and stressed the need for early treatment to control it and to 
prevent further attacks. The quick diagnosis and isolation of infected 
patients from the endemic area result in decreasing the possibility of 
pathophoresis.
Treatment of LF depends on some of the drugs such as ivermectin, 
albendazole, and diethylcarbamazine. These drugs work to dispose 
of the larval worm, to hold the reproduction of adult worm and kill 
it. Some studies showed the killing of adult worm with treatment by 
doxycycline [5,8,22,25,29,30,35,39,40].
Diethylcarbamazine citrate (DEC) is the effectively used drug for 
treatment which is capable of disintegrating the adult W. bancrofti, 
B. malayi, and B. timori [9,25,29,30,33,35,39,40]. It rapidly disintegrates 
the microfilariae but disintegrates the adult worms slowly and 
incompletely. The use of single doses of two drugs together (albendazole 
with DEC) is effective by 99% in removing microfilariae from the blood 
for a year after treatment. Although these drugs are effective but also have 
side effects, these side effects may be alleviated using antihistamines 
and/or anti-inflammatory drugs [5,8,26]. Corticosteroids can be given 
along the treatment to reduce the diethylcarbamazine side effects 
[5,41]. It is recommended to give diethylcarbamazine to persons who 
do not have microfilaremia to reduce its prevalence and density [42].
In general, the efficiency of these drugs is concentrated in the early cases 
of the disease. In chronic cases, surgical intervention is necessary such 
as hydrocele surgery and lymphoedema surgery that can be classified 
into two main stages: Surgical operations to improve the lymph flows 
and excisional operations to reduce the volume of the limb [5]. Vaccines 
are not yet available, but in 2013, the University of Illinois College of 
Medicine in Chicago was reporting about 95% efficacy in testing against 
B. malayi in mice [43].
Also the effective mosquito control is very important in lessing the 
transmission by using the larviciding and insecticides against adult 
mosquitoes [7,14].
DISCUSSION
LF is a disease caused by mosquitoes in tropical regions without clinical 
symptoms. In the case of acute infection, patients suffer from symptoms 
such as inguinal lymph nodes, fever, and skin thickening while chronic 
LF is characterized by chronic lymphedema and swelling of the limbs, 
breasts, and scrotum. For treating active filarial infection is used. The 
disease may develop so the surgery becomes necessary. Chronic filarial 
disease has serious social and economic effects.
CONCLUSIONS
Considerable achievements have been made toward the LF, further 
studies are needed to better assess the rates of prevalence and 
implement control programs recommended by the WHO.
Recent studies have led to new treatment techniques, strategies, and 
diagnostic tools that have changed the prospects of LF control.
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